“iSpecimen’s strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for the second quarter of 2024,” stated Tracy Curley, CEO of iSpecimen. “The initiatives we have completed, namely, our Next Day Quotes program, has quickly become a key focus internally for our business and has meaningfully improved our conversion rates throughout the first half of 2024. In addition, our Supplier Refresh program has allowed us to engage with our suppliers at a level not previously possible, which in turn, has contributed to increased velocity through our sales funnel and the strong results we generated for the quarter. We also continued to decrease costs through head count and other expense reductions, as we focus on driving towards profitability and increasing shareholder value.”
“During the quarter we hired Brielan Smiechowski as our new Senior Vice President of Sales & Business Development. She brings over 15 years of sales experience in life sciences and healthcare. In this role, Brielan will be leading the focus on key customer accounts as well as implementing a more robust outbound sales and business development structure,” concluded Ms. Curley.
Financial Results for the Three and Six Months Ended June 30, 2024
Revenue was approximately $2.86 million for the second quarter of 2024, an increase of 76%, compared to approximately $1.63 million for the second quarter of 2023. The increase in revenue was primarily due to an increase of 1,236 specimens, or 26%, in specimen count from 4,682 specimens in the three months ended June 30, 2023 to 5,918 specimens in the three months ended June 30, 2024. The average selling price per specimen also increased by $137, or 39%, from $347 in the three months ended June 30, 2023 to $484 in the three months ended June 30, 2024.
During the six-month period ended June 30, 2024, we reported revenue of approximately $5.15 million, compared to approximately $4.58 million during the same period last year. The increase in revenue for the six-month period ended June 30, 2024, was attributable to an increase in average selling price per specimen of $119, or 34%, from $343 in the six months ended June 30, 2023, to $462 in the six months ended June 30, 2024. The increase in average selling price per specimen was offset by a decrease of 2,152 specimens, or 16%, in specimen count from 13,311 specimens in the six months ended June 30, 2023 to 11,159 specimens in the six months ended June 30, 2024.
For the quarter ended June 30, 2024, cost of revenue increased by approximately $570,000, or 67%, from approximately $854,000 in the second quarter of 2023 to approximately $1,424,000 for the second quarter of 2024, which was attributable to a 26% increase in the number of specimens accessioned for the current period compared to the same period in the prior year, and a $58, or 32%, increase in the average cost per specimen.
Cost of revenue for the six-month period ended June 30, 2024 was approximately $2.42 million compared to approximately $2.00 million for the same period in 2023, an increase of 21%. The six-month period increase was attributable to a 45% increase in the average cost per specimen impacted by the specimen mix, offset by a 16% decrease in the number of specimens accessioned during the six months ended June 30, 2024, over the same period in the prior year.
General and administrative expenses for the three months ended June 30, 2024, decreased by approximately $703,000, or 40%, to approximately $1.05 million compared to approximately $1.76 million for the same period in the prior year. For the six-month period ended June 30, 2024, general and administrative expenses decreased by approximately $311,000, or 9%, to approximately $3.16 million compared to approximately $3.47 million during the same period in the prior year.
Net loss was approximately $2.11 million, or $(0.19) per share, for the second quarter of 2024, compared to a net loss of approximately $3.50 million, or $(0.39) per share, for the second quarter of 2023. Net loss was approximately $5.01 million, or $(0.49) per share, for the first six months of 2024, compared to a net loss of approximately $5.9 million, or $(0.66) per share, for the first six months of 2023.
As of June 30, 2024, cash and cash equivalents, along with available-for-sale securities, were approximately $2.15 million, compared to approximately $5.01 million as of December 31, 2023.
Conference Call and Webcast Information
The Company will host a conference call and audio webcast on Tuesday, August 6, 2024, at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO.
For interested individuals unable to join the conference call, a replay will be available through August 20, 2024, at +1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 1170973. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://investors.ispecimen.com/presentations/.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Phil Carlson
[email protected]
| |
| |
| iSpecimen Inc.
Condensed Balance Sheets |
| | | | | | |
| | June 30, 2024 | | December 31, 2023 |
| ASSETS | (Unaudited) | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | $ | 2,151,243 | | | $ | 2,343,666 | |
| Available-for-sale securities | | — | | | | 2,661,932 | |
| Accounts receivable – unbilled | | 1,953,632 | | | | 2,212,538 | |
| Accounts receivable, net of allowance for doubtful accounts of $700,862 and $520,897 at June 30, 2024 and December 31, 2023, respectively | | 892,814 | | | | 728,388 | |
| Prepaid expenses and other current assets | | 237,564 | | | | 292,079 | |
| Total current assets | | 5,235,253 | | | | 8,238,603 | |
| Property and equipment, net | | 104,822 | | | | 127,787 | |
| Internally developed software, net | | 5,695,166 | | | | 6,323,034 | |
| Other intangible assets, net | | 812,478 | | | | 908,255 | |
| Operating lease right-of-use asset | | 26,538 | | | | 193,857 | |
| Security deposits | | 27,601 | | | | 27,601 | |
| Total assets | $ | 11,901,858 | | | $ | 15,819,137 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | |
| Current liabilities: | | | | | |
| Accounts payable | $ | 4,205,371 | | | $ | 3,925,438 | |
| Accrued expenses | | 1,319,201 | | | | 1,540,607 | |
| Operating lease current obligation | | 29,130 | | | | 167,114 | |
| Deferred revenue | | 258,872 | | | | 415,771 | |
| Total current liabilities | | 5,812,574 | | | | 6,048,930 | |
| Operating lease long-term obligation | | — | | | | 29,130 | |
| Total liabilities | | 5,812,574 | | | | 6,078,060 | |
| | | | | | |
| Commitments and contingencies (See Note 8) | | | | | |
| | | | | | |
| Stockholders’ equity | | | | | |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 13,126,770 issued and 13,095,770 outstanding at June 30, 2024 and 9,114,371 issued and 9,083,371 outstanding at December 31, 2023 | | 1,309 | | | | 908 | |
| Additional paid-in capital | | 70,464,100 | | | | 69,104,313 | |
| Treasury stock, 31,000 shares, at cost | | (172 | ) | | | (172 | ) |
| Accumulated other comprehensive income | | — | | | | 840 | |
| Accumulated deficit | | (64,375,953 | ) | | | (59,364,812 | ) |
| Total stockholders’ equity | | 6,089,284 | | | | 9,741,077 | |
| Total liabilities and stockholders’ equity | $ | 11,901,858 | | | $ | 15,819,137 | |
| |
| iSpecimen Inc.
Condensed Statements of Operations and Comprehensive Loss
(Unaudited)
|
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2024 | | 2023 | | 2024 | | 2023 |
| Revenue | $ | 2,863,679 | | | $ | 1,625,140 | | | $ | 5,153,672 | | | $ | 4,575,339 | |
| Operating expenses: | | | | | | | | | | | |
| Cost of revenue | | 1,424,392 | | | | 853,633 | | | | 2,424,398 | | | | 2,000,545 | |
| Technology | | 911,927 | | | | 843,099 | | | | 1,823,894 | | | | 1,677,506 | |
| Sales and marketing | | 1,082,949 | | | | 977,748 | | | | 1,748,890 | | | | 2,025,346 | |
| Supply development | | 137,511 | | | | 291,360 | | | | 335,350 | | | | 614,862 | |
| Fulfillment | | 433,189 | | | | 462,672 | | | | 844,043 | | | | 891,692 | |
| General and administrative | | 1,055,376 | | | | 1,758,451 | | | | 3,159,282 | | | | 3,469,633 | |
| Total operating expenses | | 5,045,344 | | | | 5,186,963 | | | | 10,335,857 | | | | 10,679,584 | |
| | | | | | | | | | | | |
| Loss from operations | | (2,181,665 | ) | | | (3,561,823 | ) | | | (5,182,185 | ) | | | (6,104,245 | ) |
| | | | | | | | | | | | |
| Other income, net | | | | | | | | | | | |
| Interest expense | | (4,474 | ) | | | (3,535 | ) | | | (8,939 | ) | | | (7,070 | ) |
| Interest income | | 9,163 | | | | 110,882 | | | | 39,661 | | | | 225,144 | |
| Other income (expense), net | | 67,952 | | | | (29,138 | ) | | | 140,322 | | | | (29,255 | ) |
| Total other income, net | | 72,641 | | | | 78,209 | | | | 171,044 | | | | 188,819 | |
| | | | | | | | | | | | |
| Net loss | $ | (2,109,024 | ) | | $ | (3,483,614 | ) | | $ | (5,011,141 | ) | | $ | (5,915,426 | ) |
| | | | | | | | | | | | |
| Other comprehensive income (loss): | | | | | | | | | | | |
| Net loss | $ | (2,109,024 | ) | | $ | (3,483,614 | ) | | $ | (5,011,141 | ) | | $ | (5,915,426 | ) |
| Unrealized gain (loss) on available-for-sale securities | | (41 | ) | | | (18,155 | ) | | | (840 | ) | | | 688 | |
| Total other comprehensive income (loss) | | (41 | ) | | | (18,155 | ) | | | (840 | ) | | | 688 | |
| Comprehensive loss | $ | (2,109,065 | ) | | $ | (3,501,769 | ) | | $ | (5,011,981 | ) | | $ | (5,914,738 | ) |
| | | | | | | | | | | | |
| Net loss per share - basic and diluted | $ | (0.19 | ) | | $ | (0.39 | ) | | $ | (0.49 | ) | | $ | (0.66 | ) |
| | | | | | | | | | | | |
| Weighted average shares of common stock outstanding - basic and diluted | | 11,340,586 | | | | 9,033,868 | | | | 10,236,523 | | | | 9,011,644 | |
